The North America Oncology Drugs Market was worth USD 57.29 Billion in 2022 and is estimated to be growing at a CAGR of 8.44%, to reach USD 85.93 Billion by 2027.
Oncology helps study, diagnosis, and treatment of cancer. Cancer is a disease where abnormal cells grow uncontrollably and disrupt normal bodily functions. The North American oncology drugs market is predicted to be growing due to an increase in the incidence of various cancer disorders, rising healthcare expenditures, rise in popularity of advanced therapies and an increase in the geriatric population, a robust pipeline of medications, and changed FDA regulations to promote biologics drug development in the future. Furthermore, the increased awareness of cancer and the availability of cancer treatments are projected to drive market expansion. The North American oncology drugs market is also driven by technological advancements, rising incidence of various types of malignancies, increased demand for R&D activities in cancer, and growing concerns about high cancer-related death rates.
In addition, the market for oncology drugs in this region is likely to be driven by the launch of novel cancer drugs and therapies and government support to enhance healthcare conditions. New cancer drug and therapy advancements and increased knowledge of new drugs and therapies on the market are projected to open up new potential for the oncology drugs market in North America.
Personalized medications, an increase in mergers and acquisitions, new product releases, and an increase in collaborations and partnerships are some of the trends that have been seen in the pharmaceutical industry. Targeted therapy is less harmful than typical treatment alternatives in the oncology medicine industry; hence companies are investing in it. Targeted cancer therapies are medications or substances that stop cancer from spreading by interfering with molecules that are more engaged in cancer cell progression than normal cell activity.
The high expense of new medication development and the risk of failure and side effects associated with cancer drug therapies are projected to limit the market growth. Patent expiration of drugs, pricing demands from regulators, obstacles due to regulatory changes, and inadequate healthcare access were all factors that hampered expansion in the past. The high cost of cancer medicines, strict government regulations, significant investment in the development and clinical trials of therapies, and the adverse effects of cancer treatments are a few other major factors restricting the growth of the North American oncology drugs market.
This research report on the North American oncology drugs market has been segmented and sub-segmented into the following categories:
By Drug Class Type:
By Distribution Channel:
By Route of Administration:
By Drug Classification:
Geographically, the North American oncology drugs market is predicted to lead the global market during the forecast period. The region's cancer cases have been accelerated by a rapid increase in smokers combined with an increase in sedentary lifestyles. As a result, the demand for cost-effective and feasible cancer treatments, especially oncology medications, has increased significantly. Breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, and skin cancer are the most frequent malignancies in the United States.
As a result, rising cancer incidence and increased research into targeted medicines are projected to drive market expansion in the future years. Every day, cancer is projected to be diagnosed in Canadians. As a result of the factors listed, the growth of the North American oncology drugs market is predicted over the forecast period.
KEY MARKET PLAYERS:
F. Hoffmann-La Roche Ltd, Genentech, Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG are some of the notable companies in the North America oncology drugs market.
1.1 Market Definition
1.2 Scope of the report
1.3 Study Assumptions
1.4 Base Currency, Base Year and Forecast Periods
2. Research Methodology
2.1 Analysis Design
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Data Modelling
2.2.4 Expert Validation
2.3 Study Timeline
3. Report Overview
3.1 Executive Summary
3.2 Key Inferences
4. Market Dynamics
4.1 Impact Analysis
4.2 Regulatory Environment
4.3 Technology Timeline & Recent Trends
5. Competitor Benchmarking Analysis
5.1 Key Player Benchmarking
5.1.1 Market share analysis
5.1.3 Regional Presence
5.2 Mergers & Acquisition Landscape
5.3 Joint Ventures & Collaborations
6. Market Segmentation
6.1 North America Oncology drugs Market, By Type
6.2 Lung Cancer
6.3 Pancreatic Cancer
6.4 Breast Cancer
6.5 Prostate Cancer
6.6 Ovarian Cancer
6.7 Colorectal Cancer
6.8 Gastric Cancer
6.9 Kidney Cancer
6.10 Brain Cancer
6.11 Brain Cancer
6.12 Thyroid Cancer
6.12.1 Market Size Estimations & Forecasts (2022 - 2027)
6.12.2 Y-o-Y Growth Rate Analysis
6.12.3 Market Attractiveness Index
6.13 North America Oncology drugs Market, By Drug Class Type:
6.15 Targeted Therapy
6.16 Immunotherapy (Biologic Therapy)
6.17 Hormonal Therapy
6.17.1 Market Size Estimations & Forecasts (2022 - 2027)
6.17.2 Y-o-Y Growth Rate Analysis
6.17.3 Market Attractiveness Index
6.18 North America Oncology drugs Market, By Distribution Channel:
6.19 Hospital Pharmacies
6.20 Retail Pharmacies/Drug Stores
6.21.1 Market Size Estimations & Forecasts (2022 - 2027)
6.21.2 Y-o-Y Growth Rate Analysis
6.21.3 Market Attractiveness Index
6.22 North America Oncology drugs Market, By Route of Administration:
6.25.1 Market Size Estimations & Forecasts (2022 - 2027)
6.25.2 Y-o-Y Growth Rate Analysis
6.25.3 Market Attractiveness Index
6.26 North America Oncology drugs Market, By Drug Classification:
6.27 Branded Drugs
6.28 Generic Drugs
6.28.1 Market Size Estimations & Forecasts (2022 - 2027)
6.28.2 Y-o-Y Growth Rate Analysis
6.28.3 Market Attractiveness Index
7. Geographical Landscape
7.1 North America - Market Analysis (2022 - 2027)
7.1.1 By Country
7.1.2 By Type
7.1.3 By Drug Class Type:
7.1.4 By Distribution Channel:
7.1.5 By Route of Administration:
7.1.6 By Drug Classification:
8. Key Player Analysis
8.1.1 Business Description
8.1.4 SWOT Analysis
8.1.5 Recent Developments
8.1.6 Analyst Overview
8.2 Johnson & Johnson
8.4 Bristol-Meyers Squibb Company
8.5 AstraZeneca PLC
8.6 F Hoffmann-La Roche Ltd
8.7 Merck & Co
8.8 AbbVie Inc.
8.9 Astellas Pharma Inc.
8.10 Amgen Inc.
9. Market Outlook & Investment Opportunities
List of Tables
List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.